News from provention bio, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 12, 2022, 07:30 ET Provention Bio to Host a May 19, 2022 Virtual Investor Event Focused on the Potential Commercial Launch of Teplizumab Later This Year

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

May 05, 2022, 07:00 ET Provention Bio Reports First Quarter 2022 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported...

May 03, 2022, 07:30 ET Provention Bio Announces the Grant of Inducement Awards

rovention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Apr 28, 2022, 07:30 ET Provention Bio to Report First Quarter 2022 Financial Results on May 5, 2022

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Apr 04, 2022, 16:05 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 28, 2022, 07:30 ET Provention Bio Announces Positive Final Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Mar 21, 2022, 07:00 ET Provention Bio Announces FDA Acceptance of the Biologics License Application (BLA) Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 04, 2022, 16:05 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Mar 03, 2022, 07:30 ET Provention Bio to Present at Two Upcoming Virtual Investor Conferences

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Feb 24, 2022, 07:00 ET Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported...

Feb 22, 2022, 07:30 ET Provention Bio Announces Biologics License Application (BLA) Resubmission for Teplizumab to Address Complete Response Letter (CRL)

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Feb 17, 2022, 16:05 ET Provention Bio to Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Feb 10, 2022, 07:30 ET Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Feb 04, 2022, 16:05 ET Provention Bio Announces the Grant of Inducement Award

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Jan 27, 2022, 16:05 ET Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Jan 20, 2022, 16:05 ET Provention Bio Announces Initiation of the Phase 2a PREVAIL-2 Study of PRV-3279 (CD32B × CD79 Bispecific DART® Molecule) in Systemic Lupus Erythematosus (SLE)

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Jan 07, 2022, 07:30 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Jan 06, 2022, 07:30 ET Provention Bio to Present at the Virtual H.C. Wainwright BioConnect Conference

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Dec 20, 2021, 07:34 ET Provention Bio Announces Leadership Team Expansion

December 20, 2021— Provention Bio, Inc. (NASDAQ: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing...

Dec 02, 2021, 07:30 ET Provention Bio Announces the Grant of Inducement Awards

Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,...

Nov 22, 2021, 07:30 ET Provention Bio Provides Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an...

Nov 17, 2021, 07:30 ET Provention Bio Appoints Jan Hillson, M.D., as Senior Vice President of Clinical Development

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Nov 09, 2021, 08:00 ET Provention Bio Puts Type 1 Diabetes to the Test with Pledge Campaign for Diabetes Awareness Month

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Nov 05, 2021, 16:30 ET Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...

Nov 04, 2021, 07:05 ET Provention Bio Announces Appointment of Thierry Chauche as Chief Financial Officer

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced...